Organic Active Ingredients TRIZ Cases

A thiazole-linked catalyst crosses the blood-brain barrier and uses light to oxygenate tau amyloids, suppressing aggregation and toxicity.

This oral formulation releases minoxidil gradually to sustain effective serum levels and limit adverse effects from peak concentrations.

Androgen-deprivation drugs lower testosterone to slow DCM progression, improve cardiac contractility, and support survival.

Macrocyclic compounds bind MCL-1 to disrupt its anti-apoptotic function and address cancer-cell survival linked to chemoresistance.

IL-17 inhibitors block cytokine-receptor binding to address ocular inflammation, restore goblet cell function, and stabilize the tear film.

Administering cell-free amniotic fluid at the injury site within a therapeutic window addresses ischemic damage without invasive procedural trauma.

Use hematocrit-based conversion to quantify mycophenolic acid and other immunosuppressants from whole blood without separating the sample.

Small-molecule 7-azaindole compounds inhibit ActRIIB signaling to address muscle atrophy and weight loss in cancer cachexia.

Beta-cyclodextrin derivatives sequester cholesterol and inhibit immune activity to improve meibum and tear film stability.

Defined XRPD peaks identify PDE4 inhibitor crystal form I, improving stability and purity for consistent pharmaceutical delivery.

Specific chemical markers in a non-combustible aerosol composition recreate cigarette-like sensory attributes without burning.

Chemical substitutions and bicyclic ring systems help shield oligomeric compounds from nucleases while retaining RNAi function and in vivo stability.

Poor skin absorption limits topical timolol for deep infantile hemangiomas; a white vaseline–wax composition increases subcutaneous drug delivery.

Tipelukast blocks C3a receptor signaling to reduce scratching when antihistamines fail in atopic dermatitis and cholestasis.

Herpesvirus polymerase inhibition blocks viral replication, addressing resistant variants and dose-related toxicity in current treatments.

Low-yield, hard-to-scale synthesis is addressed with a two-step Suzuki coupling that reaches about 61% yield for glycolate oxidase inhibitors.

Polysaccharide nanoparticles carry anthracyclines toward tumour tissues, addressing poor targeting while limiting exposure to healthy tissue.

N-acetylated oligosaccharides such as LNnT support infant intestinal muscle thickness and motility while improving feeding tolerance.

CTO blocks calcium signaling to target SARS-CoV-2 entry and replication while limiting cytokine storm and excessive immune responses.

A PHB-binding peptide links glycyrrhizin to adipose tissue, helping inhibit adipocyte hypertrophy and reduce TNF-α secretion.

The excipient blend stabilizes 2-oxo-clopidogrel while enabling rapid, complete release from an oral solid preparation.

Heterocyclic scaffolds tune RIP1 binding and kinase selectivity to address inadequate inhibition in inflammatory and immune-related diseases.

PDHK inhibition activates PDH to promote glucose oxidation, reduce hyperglycemia, and improve energy production in ischemic tissues.

Low-dose inhibitors reduce aberrant tyrosine phosphorylation, improving cardiac function while limiting adverse effects.

Replacing trimetazidine dihydrochloride with selected salts limits nitrosamine formation below 1 ppm in nitrite-exposed formulations.

A stable 1:1:1 co-crystal addresses slow absorption and low ketoprofen solubility to improve bioavailability and pain relief.

MCC and L-HPC support high ceralasertib loading while calcium phosphate and magnesium stearate help maintain robust tablet manufacture.

Current IgAN treatments may miss alternative-pathway activation; piperidinyl-indole compounds inhibit factor B to reduce proteinuria.

This case shows how ozanimod blocks C3a receptor signaling to reduce scratching in antihistamine-resistant pruritus.

A dihydrophthalazine compound inhibits PRMT5 in MTAP-deficient cells, maintaining activity despite elevated MTA concentrations.

Lengthy infusions and stem-cell conditioning limit enzyme replacement; transduced T-Rapa cells continuously secrete α-gal A with less treatment burden.

SCD inhibition targets protein misfolding and aggregation toxicity in neural cells, offering a mechanism-based approach to neurological disorders.

Exosomes deliver spike and nucleocapsid mRNAs through multiple antigen-presentation pathways, broadening immunity without infectious virions.

Traceless linkers address uncontrolled release by joining biologically active agents to carriers for enzymatic, pH-dependent, or hydrolytic release.

See how a mannitol-based powder is reconstituted before dosing to avoid aqueous instability, simplify preparation, and improve pediatric palatability.

Current ILD treatments face efficacy and safety constraints; modified AT2 agonists improve metabolic stability and reduce CYP enzyme inhibition.

A different BTK binding mode is designed to maintain inhibitor activity against wild-type BTK and C481 mutation variants.

See how triterpene compounds inhibit SARS-CoV-2 3CLpro to block viral polyprotein processing and replication.

Because direct endocochlear potential measurement can damage the cochlea, 201Tl SPECT tracks potassium uptake non-invasively.

High-affinity compounds block HuR multimerization to address cancer and inflammation where effective inhibitors are lacking.

Pre-infused humectants lubricate dry ear canals during insertion, reduce itchiness during extended wear, and support reliable earplug attenuation.

Cellulose-based suspending agents and a surfactant limit aggregation and settling, helping preserve redispersibility during storage and sustained release after injection.

Convergent coupling of independently prepared bryostatin hemispheres cuts linear synthesis length and supports multi-gram production.

Intraperitoneal cabazitaxel nanoparticles increase local drug concentrations while reducing systemic toxicity in peritoneal cancer treatment.

See how a pressed-powder nicotine tablet uses pH regulation and sub-60-second disintegration to improve absorption while limiting throat burning.

Biodegradable polymer conjugates sustain MOR antagonist release to counter rapid metabolism, prevent renarcotization, and avoid precipitated withdrawal.

By simplifying PAM requirements, the Cas12J platform expands target selection while supporting guide-RNA-directed DNA cleavage.

Medicinal chemistry develops acylamino-bridged compounds that inhibit RIPK-1 for tumor, autoimmune, and neurodegenerative disease research.

Targeting the KIF18A–microtubule interaction blocks motor activity, offering a specific route to arrest cancer cell proliferation.

Dimensionally stable aqueous gels release water on a delay inside liquid-tight packaging, supporting controlled activation of self-destructing transdermal systems.

Targeting the FTO locus variant rs1421085 disrupts the ARID5B repressor motif, shifting adipocyte programs to resolve uncertainty in causal obesity mechanisms.

Selective 3-deazapteridinone TLR-7 agonists reduce treatment complexity and side effects while improving efficacy against melanoma and viral infections.

ASLAN003 inhibits dihydroorotate dehydrogenase to trigger apoptosis in aberrant immune cells.

Solid lipid nanoparticles resolve poor oral bioavailability of formononetin by improving stability and enabling controlled drug release.

Autoclaving loads phosphatidylcholine nanoparticles into hydrogel contact lenses, eliminating organic solvent swelling and providing sustained ocular hydration.

A pharmaceutical composition combining trigonelline and 4-hydroxyisoleucine to enhance dopaminergic activity.

Co-crystal formation with gentisic acid increases neflamapimod solubility, addressing poor water solubility of the free base.

Formula I compounds treat negative symptoms via sigma-1 modulation while reducing side effects.

A bilayer tablet pushes drug through a laser hole via swelling pressure, reducing plasma concentration fluctuations.

Separate compartments stabilize apomorphine in acid and mix it at use to prevent oxidation while enabling rapid buccal absorption.

GalNAc-conjugated dsRNA agents selectively silence hepatic LDHA, reducing oxalate production while sparing muscle tissue.

Uracil derivatives inhibit acid ceramidase to modulate intracellular ceramide levels.

Magnesium stearate coating stabilizes 5 μm pirfenidone particles, resolving handling trade-offs while reducing photodermatosis risk.

High-dose glucocorticoids mobilize novel NKT-like cells to selectively deplete malignant lymphocytes while sparing normal hematopoietic cells.

A dual-reverse thermosensitive hydrogel composition encapsulates irinotecan-loaded solid lipid nanoparticles to regulate drug release kinetics.

Shilajit components up-regulate collagen synthesis genes, resolving large molecular size barriers that prevent skin penetration and digestion.

Carbohydrate lyoprotectants maintain RNA integrity during freeze-drying, enabling ambient temperature storage without cold chain logistics.

Substituted benzimidazole scaffolds target mutated isocitrate dehydrogenase 1 to reduce oncometabolite levels in gliomas and leukemias.

Linker units connect CBI dimer drugs to antibodies, balancing structural complexity with enhanced anti-tumor activity and therapeutic efficacy.

A digital therapeutic program delivers cognitive behavioral therapy alongside pharmaceutical treatment.

Co-crystallization with nicotinamide resolves the stability solubility trade-off by enhancing etravirine dissolution and plasma levels.

A topical composition containing a PDE5 inhibitor compound promotes hair growth through localized enzymatic action.

Cyclic purine dinucleotides activate the STING pathway to overcome antigen tolerance and improve T cell persistence in cancer immunotherapy.

A Light Density Index calculates treatment-effective light doses using WST11 photosensitizer data to guide precise photodynamic therapy delivery.

Limiting low molecular weight chains below 50,000 in hole-transporting layers extends device lifetime and reliability.

Kifunensine derivatives inhibit alpha-mannosidase enzymes to increase surface CD20 expression on malignant B cells.

Detecting OPTN gene mutations resolves limited diagnostic coverage for sporadic cases by identifying specific genetic markers.

Selective PKM2 inhibitors treat cancer and diabetes by disrupting glycolysis without affecting other isoforms.

Developing multiple crystalline polymorphs of Trilaciclib improves stability and bioavailability while managing manufacturing complexity.

Sequential administration of AKT and DNA-PK inhibitors restores platinum sensitivity in resistant ovarian and lung cancers.

A drone brood and vitamin D combination redistributes calcium to enhance bone mineral density.

Administering NEU1-selective inhibitors to target sialidase activity in lung tissue.

Trans-capsular administration of specific antagonists targets TNF-alpha and IL-1beta within the joint, arresting inflammation and slowing degradation.

A quinazoline derivative acts as an antipruritic agent to suppress scratching behaviors in animal models.

A lumateperone pharmaceutical composition uses specific excipients to ensure manufacturing stability.

Topical cannabidiol composition reduces pruritus and inflammation in horses with insect bite hypersensitivity.

HER2 blocking agents inhibit specific signaling pathways to reduce fibrosis, addressing the limitation of current therapies that fail to improve lung function.

Epidithiodioxopiperazine compounds replace ineffective vasodilators by blocking arterial wall thickening and reducing right ventricle hypertrophy.

Turmeric-derived aminocurcumin compounds resist amyloid binding to neurons.

Viral vector delivers HuGlyIDUA gene to cerebrospinal fluid, enabling continuous enzyme production by transduced central nervous system cells.

A twist-to-mix drug injection apparatus integrates storage and mixing chambers to reconstitute solid medication with a diluent before administration.

Modified oligonucleotides target miR-17 to reduce kidney volume and delay end-stage renal disease progression.

Segmenting high molecular weight PEO into small multiparticulates resolves the trade-off between tamper resistance and dosage form weight.

Oil-based abiraterone prodrug depots provide sustained release to resolve low bioavailability and variable blood levels from oral dosing.

Eutectic mixture of drug and carrier eliminates cold chain storage while maintaining emulsion stability for intravenous injection.

Formula I compounds target the NS5A protein to overcome limited sustained efficacy in current Hepatitis C therapies.